Switzerland-based Virometix has enrolled all subjects in its Phase I clinical trial of peptide-based vaccine, V-212, aimed at Streptococcus pneumoniae infections.
The double-blind, randomised, placebo-controlled, first-in-human trial included 60 healthy participants aged between 18 and 45 years and is being carried out in partnership with Centre for Vaccinology (CEVAC) at Ghent University Hospital.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
V-212 is designed to address the limitations of existing pneumococcal conjugate vaccines.
Virometix CEO Anna Sumeray said: “Completing enrolment in this Phase I trial marks a significant milestone for V-212. This fully synthetic, serotype-independent vaccine candidate is designed to advance our mission of delivering scalable, safe, and broad-spectrum protection against pneumococcal disease, while addressing the current limitations of existing PCV [pneumococcal conjugate vaccine] approaches.
“Through our collaboration with CEVAC, we are well-positioned to deliver high-quality Phase I data, with topline results anticipated in the first quarter of 2026.”
CEVAC principal investigator professor Isabel Leroux-Roels said: “We are proud to collaborate with Virometix on this first-in-human study of V-212. Pneumococcal infections remain a major global health challenge, underscoring the urgent need for next-generation vaccines with broader and more durable protection.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“V-212’s fully synthetic, serotype-independent approach is highly innovative, and we look forward to advancing the clinical evaluation of this important candidate.”
The study will evaluate the tolerability and safety across low, medium, and high dose groups, as the primary goals.
Assessing immunogenicity for detecting an optimal dose for further studies is the secondary goal of the study.
V-212 is engineered as a serotype-independent, peptide-based immunogen and demonstrated long-lasting immunogenicity in preclinical models.
Virometix develops fully synthetic, structure-based nanoparticle vaccines that are designed to elicit targeted immune responses.
